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Babies born with Pompe disease require life-long treatment with 
enzyme-replacement therapy (ERT). 
Despite the human origin of the therapy, 
recombinant human lysosomal acid α 
glucosidase (GAA, rhGAA), ERT unfor-
tunately leads to the development of high 
titers of anti-rhGAA antibody, decreased 
effectiveness of ERT, and a fatal outcome 
for a significant number of children who 
have Pompe disease. The severity of dis-
ease, anti-drug antibody (ADA) devel-
opment, and the consequences thereof 
are directly related to the degree of the 
enzyme deficiency. Babies born with a 
complete deficiency GAA are said to have 
cross-reactive immunologic material 
(CRIM)-negative Pompe disease and are 
highly likely to develop GAA ADA. Less 
frequently, GAA ADA develop in CRIM-
positive individuals. Currently, GAA-
ADA sero-positive babies are treated with 
a combination of immunosuppressive 
drugs to induce immunological toler-
ance to ERT, but the long-term effect of 
these regimens is unknown. Alternative 
approaches that might redirect the 
immune response toward antigen-spe-
cific tolerance without immunosuppres-
sive agents are needed. Methods leading 
to the induction of antigen-specific reg-
ulatory T cells (Tregs), using peptides 
such as Tregitopes (T regulatory cell 
epitopes) are under consideration for 
the future treatment of CRIM-negative 
Pompe disease. Tregitopes are natural T 
cell epitopes derived from immunoglob-
ulin G (IgG) that cause the expansion 
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and activation of regulatory T cells 
(Treg). Teaching the immune system 
to tolerate GAA by co-delivering GAA 
with Tregitope peptides might dramati-
cally improve the lives of CRIM-negative 
babies and could be applied to other 
enzyme replacement therapies to which 
ADA have been induced.
Introduction
Pompe disease is a lysosomal storage 
disorder caused by a deficiency in the 
enzyme acid α-glucosidase (GAA). The 
consequence of GAA deficiency is muscle 
inflammation, disruption of muscle tissue, 
and impaired function of heart and skele-
tal muscle. Although the advent of enzyme 
replacement therapy (ERT) for Pompe 
disease has had a dramatic impact on the 
life expectancy of babies who are born 
with this disorder, treatment advances are 
still needed. Current therapy for Pompe 
disease is based on early detection of the 
genetic defect and infusions of the recom-
binant human enzyme acid α-glucosidase 
(rhGAA) to prevent glycogen accumula-
tion. Pompe-affected children who do 
not express endogenous GAA (cross-
reactive immunologic material; CRIM) 
and undergo myozyme treatment develop 
high-titer anti-drug-antibodies (ADA) 
because they are not immunologically 
tolerant to GAA. ADA decrease GAA 
enzyme uptake by muscle and/or inhibit 
its activity. High ADA titers correlate with 
poor outcomes, and even though ERT has 
prolonged the life of Pompe disease babies, 
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reduce T cell and T cell-dependent anti-
body responses, induce regulatory T cells, 
and lessen disease scores in animal models 
of inflammatory disease.18
Tregitopes have the following four 
characteristics: (1) Their sequences are 
highly conserved in IgG sequences; (2) 
They bind to MHC class II promiscu-
ously; (3) In response to Tregitopes, T 
cells that exhibit a T regulatory pheno-
type (CD4+CD25+ FoxP3+) expand in 
vitro and in vivo; and (4) Co-incubation 
of Tregitopes with target autoantigens 
such as pre-proinsulin inhibits effector T 
cell (Teff) proliferation in vitro and sup-
presses the secretion of effector cytokines 
(De Groot et al., unpublished and ref. 18).
We have more recently demonstrated 
that APCs present Tregitopes to Treg, 
engage feedback mechanisms promoting a 
tolerogenic APC phenotype, induce Treg 
expansion, and modulate antigen-specific 
effector T cell responses (De Groot De 
Groot et al., unpublished). Proportions 
of APC expressing MHC II, CD80, and 
CD86 are suppressed, consistent with 
reported effects of IVIg19 and of the IgG-
derived peptide hCDR1.20 Moreover, we 
have observed significant increases in pro-
portions of IL-10-producing CD4+CD25+ 
FoxP3-expressing Treg in the presence 
of Tregitopes. The basic mechanism of 
Tregitope tolerance induction is currently 
proposed to be as follows: (1) APC present 
Tregitopes to nTreg, (2) nTreg are acti-
vated to proliferate and produce IL-10, (3) 
nTreg provide tolerogenic feedback signals 
to APC, modulating the APC pheno-
type, and (4) nTreg and tolerogenic APC 
together suppress antigen-specific T cell 
responses (De Groot et al., unpublished).
In Vivo Studies with Tregitopes
Modulation of T cell responses with 
Tregitopes may contribute to the design 
of new approaches for the treatment of 
autoimmune and inflammatory diseases 
via expansion of Tregs in vivo or ex vivo. 
Experience with IVIg gives an example of 
the therapeutic potential of this approach, 
and evidence is accumulating that 
Tregitopes provide beneficial immuno-
modulatory effects that in many respects 
parallel IVIg. Within our collaborative 
Tregitope network, we have performed a 
critical unmet medical with broad-reach-
ing implications for other replacement-
protein therapies that are also limited by 
ADA (the Lysosomal Storage Disorders, 
Hemophilia A and B, etc.).10-12
Natural Regulatory T cells,  
Tregitopes and Tolerance  
Induction
Autoreactive T cells with moderate T cell 
receptor (TCR) affinity are known to 
escape deletion in the thymus to circulate 
in the periphery where they function as 
‘natural’ regulatory T cells (nTreg) by sup-
pressing immunity against self-antigens.13 
Induced Tregs (iTregs), also known as 
adaptive Tregs, are generated from circu-
lating T effector cells; these cells perform 
similar functions but have more plasticity. 
It has become increasingly clear that both 
nTregs and iTregs contribute to immune 
regulation in the periphery and that their 
presence, or absence, contributes to the 
induction of tolerance and the develop-
ment of autoimmunity and inflammation, 
respectively.
One of the most fundamental ques-
tions about nTreg cells has been their 
antigen-specificity. We surmised that 
autologous proteins, such as immuno-
globulin G (lgG), contain nTreg epitopes. 
The presence of nTreg epitopes in lgG 
might explain why immunoglobulins, 
which undergo somatic hypermutation in 
the periphery, do not elicit the expected 
immune response against the new ‘for-
eign’ hypervariable sequences. After dis-
covering highly promiscuous MHC class 
II epitopes in the constant region of IgG, 
we proposed that these epitopes were 
nTreg epitopes (Tregitopes)14 that provide 
inherent inhibitory signals to counter-bal-
ance any stimulatory signals that might 
result from neo-epitopes expressed in Ab 
hypervariable region.15 Two independent 
publications support our hypothesis: 
Ephrem and colleagues showed that intra-
venous immunoglobulin G (IVIg) induces 
nTreg,6 and Anthony and Ravetch dem-
onstrated the a linkage between immuno-
globulin binding to surface receptors that 
are associated with antigen-processing 
pathways, and Treg induction by IVIg.16,17 
We describe here our acquired knowledge 
on the ability of Tregitope peptides to 
most CRIM-negative Pompe infants who 
have complete GAA deficiency will even-
tually succumb to the disease if they are 
not treated with tolerance-inducing drugs.
The development of experimental 
immune tolerance regimens to inhibit 
ADA against life-saving enzyme replace-
ment therapy is an active area of investi-
gation. Current approaches for mitigating 
GAA-ADA are based on treatment with 
methotrexate (MTX) to inhibit the pro-
liferation of lymphocytes and Rituximab 
(Rituxan) to deplete antibody (Ab)-
producing B cells.1-3 These approaches, 
however, share significant limitations. 
Namely, these treatments are not effec-
tive in eliminating long-lived plasma cells, 
thus the timing of intervention in patients 
experiencing an ADA response is critical. 
Additional pharmacological agents that 
suppress antibody production by long-
lived plasma cells might be of use, such as 
a drug currently in use for plasma cell leu-
kemia and multiple myeloma, Bortezomib 
(Velcade).4 However, the long-term effects 
of Rituximab and Bortezomib, that both 
suppress the immune system systemically, 
are as yet unknown. Finally, the associa-
tion between the use of Rituximab and 
development of certain infections has 
been reported.5
In addition to these strategies aimed 
at inhibiting proliferation or eliminating 
lymphocyte subsets participating in the 
ADA response are those aimed at modu-
lating the immune system to become tol-
erant to the therapeutic protein. IVIG has 
been shown to be associated with modula-
tion of the regulatory T cell axis, including 
induction of nTregs;6 reduction of IL-17,7 
and by enhancing the suppressive function 
of Tregs.8 It has thus been applied with 
much success in a number of autoimmune 
diseases. A recent report describes the 
clinical outcomes in two Pompe patients 
who had received prolonged Rituximab 
therapy for ADA who were also placed 
on chronic IVIG in an effort to decrease 
infectious complications. The addition of 
IVIG may have provided an additional 
immunomodulatory benefit in promoting 
tolerance to the GAA therapy.9
Therapies that safely and perma-
nently harness the immune system to 
induce long-lasting and specific tolerance 
in Pompe disease children will address a 
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lupus erythematosus (SLE35), idiopathic 
thrombocytopenic purpura (ITP) and 
chronic inflammatory demyelinating 
polyneuropathy (CIDP).36-41 Of rel-
evance to the goal of inducing tolerance 
to rhGAA, IVIg has been used to reduce 
ADA in Pompe patients undergoing 
Myozyme treatment.9 See Table 1 for a list 
of experiments that have been performed 
with Tregitope, the human disease paral-
lel, and a comment on current therapy for 
that condition (highlighting the potential 
role of Tregitope in the future therapy of 
the condition).
How Could Tregitopes be Applied 
to Pompe Disease Therapy?
We believe Tregitopes are natural, human 
regulatory T cell epitopes (“Tregitopes”) 
present in the Fc and Fab domains of IgG 
incorporation of Tregitopes in drug design 
may aid in the design of improved toler-
ance-inducing therapies, and safer, more 
effective protein therapeutics.
Natural (n)Treg participate in cen-
tral tolerance by controlling immune 
responses to autologous proteins, and 
in peripheral tolerance by stimulating 
induced (i)Treg cells.22 Induction of iTreg 
is associated with sustained tolerance to 
transplants, allergens and autologous pro-
teins.13,23,24 Tolerance can be induced with 
non-depleting anti-CD4 antibodies25,26 
and with AAV vector-mediated expres-
sion of antigens in the liver,27 including 
rhGAA.28-30 IVIg, a source of Tregitopes, 
induces tolerance in a number of different 
settings such as solid organ transplant,31 
eradication of FVIII and FIX inhibitory 
antibodies in hemophilia patients,32-34 and 
autoimmune diseases such as systemic 
number of studies to probe potential thera-
peutic applications of Tregitopes in mouse 
models of MS (EAE), cardiac transplant, 
diabetes (NOD), antigen-induced airway 
hyper-responsiveness, and modulation of 
viral vector immunogenicity in adeno-
associated virus (AAV)-mediated gene 
transfer.21 Together, the results obtained 
in these models show that Tregitopes co-
administered with proteins suppress anti-
gen-specific T cell and antibody responses, 
and induce expansion of functional 
Tregs. Side-by-side in vivo comparisons 
of Tregitope with IVIg have been per-
formed in the autoimmune EAE model 
[Khoury and Elyaman, personal com-
munication] and antigen-induced aller-
gic airway disease [Mazer and Massoud, 
personal communication], demonstrat-
ing that IVIg effects can be replicated by 
Tregitope administration. Adaptation or 
Table 1. Overview of tregitope in vivo experiments and results
Experimental model Finding
Human disease 
parallel
Current clinical 
therapy
In vivo controls Source
OVA-specific tolerance in 
C57BL/6 mice
Suppression of t cell  
proliferation; Suppression of 
OVa-antibody titer
enzyme 
replacement 
therapy
Immune 
tolerance 
Induction
Influenza Ha 
(negative Ctr) 
no effect; 
IVIG Ctr similar to 
tregitope
L. Cousens, a. De 
Groot (epiVax)
OVA-specific  
tolerance in DO11.10 
TCR Transgenics
Suppression of t cell  
proliferation; induction of 
antigen-specific tregs
enzyme 
replacement 
therapy
Immune 
tolerance 
Induction
Influenza Ha 
peptide: 
no effect
D.Scott, 
y. Su 
(USUHS)
EAE prevention with 
Tregitope
In C57Bl/6
reduction of eae  
symptoms; induction of 
tregs
multiple 
Sclerosis
Copaxone; 
Interferon β
tysabri; Campath
OVa peptide  
(negative Ctr) 
no effect; 
IVIG Ctr similar to 
tregitope
S.Khoury; 
W. elyaman 
(Brigham)
OVA Allergy Model; 
Therapy with Tregitope 
vs. IVIG
reduction of allergic 
response to OVa and airway 
reactivity, increase in treg 
Induction
allergy
anti-histamines, 
Immune 
tolerance 
Induction
albumin (negative Ctr) 
no effect; 
IVIG Ctr similar to 
tregitope
B. mazer, 
a. massoud 
(mcGill)
Tregitope in AAV; 
TNBS-induced model of 
inflammatory colitis
reduction of clinical and 
histological severity, 
increased treg infiltration in 
the colon
Crohn’s Disease
azathiaprine, anti-
tnF mabs, Steroids
Saline; no effect
V. Ferreira, S. 
van der marel 
(UniQure)
Tregitope in AAV for 
Gene Transfer
Suppressed CD8+-t cell 
response to aaV epitope in 
gene transfer model
Gene transfer
Gene transfer 
Vectors cur-
rently induce CtL 
response
Scrambled tregitope 
peptide  
(negative Ctr) 
no effect
F. mingozzi 
(CHOP)
Tregitope in T1D (NOD 
model)
with insulin peptides
Suppressed development of 
diabetes; effect enhanced 
when tregitope co-deliv-
ered with insulin
type I Diabetes Insulin therapy
PPI peptides, tettox 
peptide  
(negative Ctr) 
 no effect
L. Cousens, 
a. De Groot 
(epiVax)
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ability to reduce the development of 
inflammation in the TNBS model of 
colitis [van der Marel, personal commu-
nication]. This reduction in inflamma-
tion was associated with an increase in the 
presence of Tregs in the intestinal mucosa, 
lamina propria and the thymus of AAV5-
Tregitope167-treated mice. Additionally, 
expression of both Foxp3 and GARP were 
increased in the thymic CD4+ T lym-
phocyte population in mice pre-treated 
with AAV5-Tregitope167 but not in mice 
treated with saline alone, suggesting that 
Tregitope treatment increased activation 
of regulatory T-cells.47-51 The presence of 
higher numbers of activated regulatory T 
cells in the AAV5-Tregitope-treated mice 
corresponded with the prevention of ful-
minant intestinal inflammation in vivo, in 
this TNBS model of inflammatory bowel 
disease.
These two studies demonstrate that 
AAV vector-mediated co-delivery of 
Tregitopes with the enzyme replacement 
therapies could represent an alternative 
Tregitope-based approach to induce spe-
cific tolerance to GAA.
Conclusions
Much progress has been made in the field 
of enzyme-replacement therapy over the 
past decade. New treatments are reaching 
patients, and approaches that lead to the 
reduction of ERT-ADA are under evalu-
ation. Despite these significant advances, 
the long-term effects of current immune 
tolerance induction regimens have yet to be 
defined. Proof-of-principle for Tregitopes 
in treating ADA in the context of Pompe 
disease would have an immediate impact 
on the field of enzyme replacement ther-
apy and could accelerate adaptation of 
Tregitope therapy in the treatment of 
these children. Tregitopes merit consider-
ation even if they only reduce dependence 
on immunosuppressive drugs, however 
ongoing studies appear to indicate that 
Tregitopes elicit antigen-specific toler-
ance, augmenting the potential benefits of 
this approach in mitigating ADA. Thus, 
further proof-of-principle studies with 
Tregitopes are likely to have a far-reaching 
impact on the clinical development of bio-
logic therapies, including enzyme replace-
ment therapy for Pompe disease.
GAA show an initial robust expression of 
GAA that is rapidly inactivated by ADA 
responses.43-45 Low dose and liver-specific 
expression of therapeutic enzymes may 
lead to Treg-mediated tolerance,29 an effect 
that may be enhanced by delivering GAA 
fused to Tregitopes. EpiVax’ Tregitope col-
laborators Mingozzi and High (Children’s 
Hospital of Philadelphia) have tested the 
concept of Tregitope-induced tolerance 
using AAV vectors in which Tregitopes are 
fused to the expressed transgene.
To summarize their results: an AAV 
vector expressing a protein antigen fused 
to Tregitopes (or ‘scrambled’ Tregitopes as 
a control) between which was engineered 
a PACE/furin sequence that is suscep-
tible to cleavage by intracellular proteases. 
C57BL/6 mice received the Tregitope-fused 
vector (or the scrambled control, n = 4 per 
group). Four weeks later, mice were chal-
lenged with an adenoviral vector expressing 
the antigen to trigger a strong CD8+ T cell 
response against it.46 Ten days later, at the 
peak of T cell responses triggered by the 
adenoviral challenge, mice were sacrificed. 
Tregitope co-delivery in this gene transfer 
model effectively suppressed the develop-
ment of effector (CD8+) T cell responses 
[Mingozzi and De Groot, unpublished].
Similarly, van der Marel et al. have 
tested an AAV-5 vector carrying a human 
Tregitope167-expressing cassette for its 
that may be responsible for tolerance to 
idiotypic epitopes (Fig. 1). When incu-
bated with peripheral blood mononuclear 
cells (PBMCs) in vitro, Tregitopes spe-
cifically activate CD4+ T cells, increase 
CD25/Foxp3 expression, and increase 
expression of regulatory cytokines and che-
mokines.13 Administration of Tregitopes 
with protein antigens in vivo inhibits T 
cell proliferation and effector cytokine 
expression. Tregitope effects are long- 
lasting in a range of disease models (Table 1); 
duration of effect extends at least 26 weeks 
in NOD-T1D or 100 d in transplant (De 
Groot et al., unpublished).42
As shown in Table 1 for T1D (last 
row), co-administration of Tregitopes 
with the antigen leads to even greater sup-
pression of in vivo cytokine production, 
T cell response, and antibody titers. The 
combined efficacy of target antigen and 
Tregitope, administered together, suggests 
that Tregitopes induce antigen-specific 
tolerance. This approach is deserving of 
further investigation in Pompe disease 
models.
Gene Transfer and Tregitopes
Gene transfer of GAA is under consid-
eration as a therapy for Pompe disease. 
Several studies in GAA-KO mice test-
ing the AAV vector-driven expression of 
Figure 1. Hypothesized tregitope mechanism of action. treg epitopes (tregitopes) present in 
Fc and Fab domain of IgG drive tolerance to neo-epitopes pre-sent in the Fab hypervariable 
domains. epiVax discovered conserved t -cell epitopes in IgG that engage natural treg. We hy-
pothesize that tregitopes (dark blue) activate treg that lead to bystander suppression of effector t 
cells that recognize effector epitopes (red) and, depending on the context, induction of antigen-
specific tregs (atregs) to these epitopes.
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